DANA FAYYAD: Open Payments
NPI 1417434085 · FAIRFAX, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$484 in 22 payments from 7 companies in 2025. Trend: 2023 $386 · 2024 $1,027 · 2025 $484
Food & beverage: $484
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 7 | $140 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $135 |
| ABBVIE INC. | 5 | $102 |
| Aimmune Therapeutics, Inc. | 1 | $34 |
| GENZYME CORPORATION | 1 | $29 |
| Gilead Sciences, Inc. | 1 | $23 |
| PFIZER INC. | 1 | $22 |
Products named: TREMFYA, XIFAXAN, RINVOQ, VOWST, DUPIXENT, XELJANZ, SKYRIZI, CREON.
Industry payments across VA — which companies pay providers there.
